Outcome of Board Meeting

Date: July 10, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Dalal Bandra (E), Mumbai-400051 Street Fort, Mumbai- 400001 Symbol: ORCHPHARMA Scrip Code: 524372 Sub: Intimation under Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("SEBI Listing Regulations"). Dear Sir/ Ma’am, In terms of Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and in continuation of our earlier intimation dated July 10, 2026, with respect to scheme becoming effective from July 10, 2026 and consequent dissolution of Dhanuka Laboratories Limited (“Amalgamating Company/DLL”) without being Wound up, we wish to inform you that the Board of Directors of the Company, at its Meeting held today i.e., July 10, 2026, concluded at 19:10 P.M. have, inter alia, considered, noted and approved the following: - Effectiveness of Scheme: Pursuant to completion of all the conditions as prescribed under Clause 8 of the Scheme, the Scheme has been made effective today, i.e., July 10, 2026 (“Effective Date”) and Amalgamating Company stand dissolved without being wound up in accordance with the terms of the Scheme. - Appointed Date: The Appointed date as per the scheme is 1st April, 2024. - Alteration of Capital Clause of Memorandum of Association: Pursuant to the effectiveness of the Scheme, the authorized share capital has automatically stood increased on account of transfer to and amalgamation of authorised capital of DLL with the authorized share capital of Orchid Pharma Limited (“Amalgamated/OPL”). Accordingly, Clause V of the Memorandum of Association (MoA) of OPL, has stood replaced by the following Clause V: V. The Authorised Share Capital of the Company is Rs. 164,51,00,000 (rupees one hundred sixty four crore and fifty one lakh only) divided into 16,45,10,000 (sixteen crore forty five lakh ten thousand only) equity shares of Rs. 10/-(rupees ten only) each. - Fixing of Record date: Pursuant to regulation 42 of SEBI Listing Regulations and in consultation with the Amalgamating Company the record date for determining the shareholders of the Amalgamating Company to whom the shares in Amalgamated Company would be issued under the Scheme is Thursday, 23rd July, 2026. - Share Exchange Ratio: Pursuant to Para 16 of Part III of Scheme share exchange ratio is as follows: "161 fully paid up equity shares of face value of INR 10/- (Indian Rupees Ten) of the Amalgamated Company to be issued and allotted to the members of the Amalgamating Company against 5 fully paid up equity share of face value of INR 100/- (Indian Rupees One Hundred) each held in the Amalgamating Company." You are requested to take the above intimation on record. Thanking You For Orchid Pharma Limited Kapil Dayya Company Secretary & Compliance Officer Membership No.:F10698 Orchid Pharma Limited Regd. Office: Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Dist-603110, Tamil Nadu, India Phone: (91)-44- 2744 4471/72/73 Email: Corporate@orchidpharma.com Website: www.orchidpharma.com CIN: L24222TN1992PLC022994